First day of trading with warrants of series TO4

As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the current shareholders in the Company for the dilution that the previously conducted directed issue of shares and warrants entails. In this context, the Company simultaneously announces that the first day for trading with warrants of series TO4 on Nasdaq First North Growth Market has been set to November 30, 2020.

Terms and information regarding warrants of series TO4

A total of 6,003,157 warrants of series TO4 have been issued, of which 4,075,000 were issued to investors in the Directed Issue, and 1,928,157 were issued to the current shareholders in the Company.

Each warrant of series TO4 will give the holder the right to subscribe for one (1) new share in Cyxone at a subscription price corresponding to 70 percent of the average volume-weighted share price on Nasdaq First North Growth Market during the period from April 29, 2021 to May 1. However, the subscription price shall not exceed SEK 7.05 per new share, and not be less than SEK 2.00 per share. The exercise period for the subscription of new shares with warrants of series TO4 will be from May 17, 2021 up until May 28, 2021.

If all the warrants of series TO4 are exercised for the subscription of new shares, and under the condition that the share price during the measurement period is SEK 10 or higher, Cyxone can receive, at most, an additional SEK 42 million.

Upon full exercise of the warrants of series TO4, the dilution will amount to approximately 9.37 percent, in proportion to the number of shares after the registration of the Directed Issue.

Advisers

Mangold Fondkommission AB acted as the sole bookrunner and financial adviser, and Fredersen Advokatbyrå AB acted as the legal adviser in connection with the directed issue and the allotment of warrants to current shareholders in Cyxone.

Disclaimer

This is a translation of the original Swedish version of the press release. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.

Contact

Tara Heitner, CEO

Tel: +46 (0)70 781 88 08

Email: tara.heitner@cyxone.com

Adelgatan 21

211 22 Malmö, Sweden

Certified Adviser

Mangold Fondkommission AB

Telephone: +46 (0)8 503 015 50

E-mail: ca@mangold.se

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com.

Tags: